The minibodies are inert in the body but can be used monitor immune activity, such as the infiltration of CD8 ... drug on the market – PD-L1 inhibitor Imfinzi (durvalumab) which made almost ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been recommended for approval by the European Medicines Agency’s human medicines committee to treat adults ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its drug Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as a treatment for adult patients with ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that its Imfinzi (durvalumab) has been recommended for approval in the European Union to treat muscle-invasive ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its drug Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as a treatment for adult patients with ...

(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab, therapy has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer. The Cambridge ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from ...

AstraZeneca received a positive recommendation from the European Medicines Agency for its cancer therapy Imfinzi, marking a significant advancement in its oncology portfolio. Despite this ...

WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® (durvalumab) combined with standard-of-care Bacillus ...